Fung, M. & Babik, JM COVID-19 in immunocompromised hosts: what we know so far. Clin. infect Dis. 72340–350 (2021).
Article CAS Google Scholar
Becerril-Gaitan, A. et al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in cancer patients: a systematic review and meta-analysis. Eur. J. Cancer. 160243–260 (2022).
Article CAS Google Scholar
Shrotri, M. et al. Collaborative collaboration virus. Spike-antibodies waning after the second dose of BNT162b2 or ChAdOx1. Lancet 398385–387 (2021).
Article CAS Google Scholar
Chemaitelly, H. et al. Decreased protection of BNT162b2 vaccine against SARS-CoV-2 infection in Qatar. N. English. J. Med. 3861804–1816 (2021).
Google Scholar
Wang, Z. et al. Antibodies elicited by mRNA vaccine against SARS-CoV-2 and circulating variants. Nature 592616–622 (2021).
Article ADS CAS Google Scholar
Collier, DA et al. Sensitivity of SARS-CoV-2 B.1.1.7 to antibody elicited by mRNA vaccine. Nature 593136–141 (2021).
Article ADS CAS Google Scholar
Schmidt, AL et al. COVID-19 vaccination and breakthrough infections in cancer patients. Ann. Oncol. 33340–346 (2022).
Article CAS Google Scholar
As, N. et al. Three doses of a Covid-19 mRNA vaccine in solid organ transplant recipients. N. English. J. Med. 385661–662 (2021).
Article Google Scholar
Hall, VG et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. English. J. Med. 3851244–1246 (2021).
Article Google Scholar
Barrera, J. et al. Third dose of anti-SARS-CoV-2 vaccine for cancer patients: should humoral responses be monitored? A position paper. Eur. J. Cancer. 162182–193 (2022).
Article Google Scholar
Van Tilbeurgh, M. et al. Predictive markers of immunogenicity and efficacy for human vaccines. Vaccines (Basel) 9579. (2021).
Article CAS Google Scholar
Feng, S. et al. Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. night with 272032–2040 (2021).
Khoury, DS et al. Levels of neutralizing antibodies are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. night with 271205–1211 (2021).
Article CAS Google Scholar
Krammer, F. A correlate of protection is urgently needed for SARS-CoV-2 vaccines. night with 271147–1148 (2021).
Article CAS Google Scholar
Sette, A. and Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. cell 184861–880 (2021).
Article CAS Google Scholar
Frightened, EM et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematological cancer. night with 271280–1289 (2021).
Article CAS Google Scholar
Shroff, RT et al. Immune responses to two and three doses of BNT162b2 mRNA vaccine in adults with solid tumors. night with 72002–2011 (2021).
Article Google Scholar
McKenzie, DR et al. Humoral and cellular immunity to the second delayed dose of BNT162b2 SARS-CoV-2 mRNA vaccination in cancer patients. Cancer cell 391445–1447 (2021).
Article CAS Google Scholar
Fendler, A. et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern after vaccination in cancer patients: the CAPTURE study. born cancer 21321–1337 (2021).
Article CAS Google Scholar
Ehmsen, S. et al. Antibody and T cell immune responses after COVID-19 mRNA vaccination in cancer patients. Cancer cell 391034–1036 (2021).
Article CAS Google Scholar
Moro, MB et al. Humoral and cellular responses to SARS-CoV-2 mRNA vaccines in patients with a history of CD20 B-cell depletion therapy (RituxiVac): an open-label, single-center, single-initiated study researcher. Lancet Rheumatol. 3e789–e797 (2021).
Article Google Scholar
German, A. et al. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer cell 391442–1444 (2021).
Article CAS Google Scholar
AdviseDx SARS-CoV-2 IgG II. Package insert. Abbott Laboratories; 2021. Accessed February 6, 2021. https://www.fda.gov/media/146371/download.
Nandakumar, V. et al. Evaluation of a new multiplex platform for the simultaneous detection of IgG antibodies against the 4 main antigens of SARS-CoV-2. J. Appl. laboratory Med. 7698–710 (2022).
Article Google Scholar
Nelly, F. et al. Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: results from the Vax-On-Profile study. International Immunopharmacol. 108108774. (2022).
Article CAS Google Scholar
BD FACSCanto™ software. Accessed February 6, 2021. https://www.bdbiosciences.com/en-eu/products/software/instrument-software/bd-facscanto-clinical-software.
Nelly, F. et al. Effects of active cancer treatment on the safety and immunogenicity of the mRNA-BNT162b2 COVID-19 vaccine: preliminary results from the Vax-On prospective observational study. Ann. Oncol. 33107–108 (2022).
Article CAS Google Scholar
Fenioux, C. et al. SARS-CoV-2 antibody response to 2 or 3 doses of BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. 8612–617 (2022).
Article Google Scholar
Ligumsky, H. et al. Immunogenicity and safety of BNT162b2 mRNA vaccine boost in actively treated cancer patients. Lancet Oncol. 23193–195 (2022).
Article CAS Google Scholar
Zeng, C. et al. COVID-19 mRNA booster vaccines elicit strong protection against Omicron SARS-CoV-2 variant in cancer patients. Cancer cell 40117–119 (2022).
Article CAS Google Scholar
Fendler, A. et al. Omicron neutralizing antibodies after the third dose of COVID-19 vaccine in cancer patients. Lancet 399905–907 (2022).
Article CAS Google Scholar
Cheng, MP et al. Serodiagnosis for severe acute respiratory syndrome related to coronavirus-2: a narrative review. Ann. Med. International 173450–460 (2020).
Article Google Scholar
Fendler, A. et al. Immune responses after the third vaccination against COVID-19 are reduced in patients with hematological tumors compared to patients with solid cancers. Cancer cell 240114–116 (2022).
Article Google Scholar
Gascue, A., Merino, J. & Paiva, B. Flow cytometry. Hematol. Oncol. Clin. north Am. 32765–775 (2018).
Article Google Scholar
Griffiths, JI et al. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc. birth Acad. Saber USA 11716072–16082 (2020).
Article ADS CAS Google Scholar
de Goeje, PL et al. Induction of peripheral effector CD8 T-cell proliferation by the combination of Paclitaxel, Carboplatin and Bevacizumab in patients with non-small cell lung cancer. Clin. Cancer Res. 252219–2227 (2019).
Article Google Scholar
Okamoto, A. et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 63230–3233 (2022).
Article CAS Google Scholar
Maine, GN et al. Clinical and analytical evaluation of the Abbott AdviseDx SARS-CoV-2 IgG quantitative test and comparison with two other serological tests. J. Immunol. methods 503113243. (2022).
Article CAS Google Scholar
Fiekin, DR et al. Evaluation of vaccine efficacy against severe disease of COVID-19 caused by the omicron variant. Report of a meeting of the World Health Organization. vaccine 403516–3527 (2022).
Article Google Scholar
Wang, Y. Standardized neutralizing antibody assays are needed to evaluate vaccines against COVID-19. EBioMedicina 73103677 (2022).
Article Google Scholar